Two-year maintenance therapy with olaparib improves PFS in newly diagnosed patients with advanced ovarian cancer with a BRCA1 or 2 mutation.
A major trial has demonstrated that fulvestrant–palbociclib combination therapy may prolong survival and delay the need for chemotherapy in women with advanced breast cancer.
Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
A new study, published in CNS Oncology estimates the survival benefit of adding tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.